论文部分内容阅读
目的：了解米非司酮对晚期妊期促宫颈成熟的有效性及安全性。方法：应用米非司酮及蒂洛安对100例单胎头位初产妇进行妊娠晚期促宫颈成熟效果的对比观察（随机分为2组，各50例）。结果：总有效率：米非司酮90％，蒂治安90％，两者比较，差异无显著性意义（P＞0．05），各组用药前后宫颈评分明显升高（P＜0．001），但两组间比较差异无显著性（P＞0．05）。用药前后胎心电子监护测定，两组异常发生率、胎儿窘迫发生率及新生儿Apgar评分差异均无显著性。结论：米非司酮（50mg口服q12h）用于妊娠晚期促宫颈成熟安全有效。
Objective: To understand the efficacy and safety of mifepristone in promoting cervical ripening in late pregnancy. Methods: The effects of mifepristone and tilaloan on the development of cervical pregnancy induced by late pregnancy in 100 primiparous single head women were compared (randomly divided into two groups, 50 cases each). Results: The total effective rate was 90% for mifepristone and 90% for teichionide. There was no significant difference between the two groups (P> 0.05) ), But there was no significant difference between the two groups (P> 0.05). Before and after treatment of fetal heart rate monitoring, two groups of abnormal incidence, the incidence of fetal distress and neonatal Apgar scores were no significant difference. Conclusion: Mifepristone (50mg orally q12h) is safe and effective for cervical ripening in late pregnancy.